Bright Minds Biosciences' Investigational New Drug Application For Developmental And Epileptic Encephalopathies And Related Protocol BMB-101-105 Has Been Placed On Partial Clinical Hold Following FDA Review
The proposed trial related to this IND is a randomized, placebo-controlled, double-blind Phase 2 study designed to evaluate the efficacy and safety of ascending doses of BMB-101, up to a maximum tolerated dose, for the
A medicine company's drug test got paused by the FDA for safety review. When a test pauses, watch to see if the company can fix concerns and restart it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.